Previous 10 | Next 10 |
BOSTON and JERUSALEM, May 16, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appointment of Miranda Toledano, one of Entera’s existing board members, as Chief Business Officer, ...
Journey Medical Corporation (DERM) Q1 2022 Earnings Conference Call May 10, 2022 16:30 ET Company Participants Jose Ibrahim - IR Claude Maraoui - Co-Founder, President and Chief Executive Officer Ernie De Paolantonio - Chief Financial Officer Ramsey Alloush - General Counsel Conference Call P...
Journey Medical press release (NASDAQ:DERM): Q1 GAAP EPS of -$0.08 beats by $0.23. Revenue of $23.3M (+117.4% Y/Y) beats by $1.14M. For further details see: Journey Medical GAAP EPS of -$0.08 beats by $0.23, revenue of $23.3M beats by $1.14M
Generated record revenue of $23.3 million for the first quarter of 2022 First patient dosed in Phase 3 clinical program evaluating DFD-29 for the treatment of papulopustular rosacea Company to hold conference call on May 10, 2022 at 4:30 p.m. ET SCOTTSDALE, Ariz., ...
SCOTTSDALE, Ariz., May 03, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological co...
SCOTTSDALE, Ariz., April 04, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological ...
MIAMI, April 01, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today ann...
Journey Medical press release (NASDAQ:DERM): Q4 Non-GAAP EPS of -$0.93. Revenue of $17.52M (+27.7% Y/Y) misses by $2.88M. Shares -1.53% AH. For further details see: Journey Medical Non-GAAP EPS of -$0.93, revenue of $17.52M misses by $2.88M
Generated record net product revenues of $63.1 million for the full year 2021 Completed initial public offering of common stock and raised $30.6 million in net proceeds Dosed first patient in Phase 3 clinical program evaluating DFD-29 for the treatment of papulopustular ...
SCOTTSDALE, Ariz., March 18, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological ...
News, Short Squeeze, Breakout and More Instantly...
Journey Medical Corporation Company Name:
DERM Stock Symbol:
NASDAQ Market:
Journey Medical Corporation Website:
SCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescriptio...
Journey Medical Corporation (NASDAQ: DERM) is the focus of IBN's latest stock spotlight. The company's shares have moved -1.78% on the day to $5.51. Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological condi...
2024-07-07 18:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...